In a patient taking tirzepatide (Mounjaro) who develops constipation, what prescription laxative is recommended?

Prescription Laxative for Mounjaro-Induced Constipation

Start with polyethylene glycol (PEG) 17 g daily as your first-line prescription laxative for constipation in patients taking Mounjaro (tirzepatide). 1

Rationale and Treatment Algorithm

Constipation is a recognized gastrointestinal side effect of Mounjaro 2, and while the FDA label acknowledges GI adverse reactions, it does not provide specific laxative recommendations. Therefore, we rely on the 2023 AGA-ACG guidelines for chronic constipation management 1.

First-Line: Osmotic Laxatives

Polyethylene glycol (PEG) is the optimal initial prescription choice because:

• Cost-effective ($10-45/month)
• Proven durable response over 6 months
• No clear maximum dose, allowing titration based on response
• Can be adjusted for symptom control and side effects 1

Alternative osmotic agents if PEG is not tolerated:

• Lactulose 15 g daily - particularly useful if the patient has other indications, though bloating/flatulence may be limiting 1
• Magnesium oxide 400-500 mg daily - avoid if renal insufficiency present 1

Second-Line: Stimulant Laxatives

If osmotic laxatives fail after adequate trial and dose titration:

Bisacodyl 5 mg daily (can increase to 10 mg daily maximum) 1

• Recommended for short-term use or rescue therapy
• Side effects include cramping and abdominal discomfort
• Long-term safety data are limited 1

Senna 8.6-17.2 mg daily is an alternative stimulant option 1

Third-Line: Prescription Secretagogues

For severe or refractory cases unresponsive to the above:

• Lubiprostone 24 μg twice daily ($374/month) - chloride channel activator 1
• Linaclotide 72-145 μg daily ($523/month) - may benefit abdominal pain 1
• Plecanatide 3 mg daily ($526/month) 1
• Prucalopride 1-2 mg daily ($563/month) - 5-HT4 agonist 1

Critical Safety Considerations

Monitor for dehydration-related complications: Mounjaro causes nausea, vomiting, and diarrhea, which combined with laxative use can lead to severe dehydration and acute kidney injury 2. Monitor renal function when initiating or escalating laxatives, especially in patients with baseline renal impairment.

Avoid in severe gastroparesis: Mounjaro delays gastric emptying and has not been studied in severe gastrointestinal disease 2. Exercise caution with aggressive laxative regimens in this context.

Common pitfall: Do not immediately reach for stimulant laxatives. The evidence supports starting with osmotic agents, which have better long-term safety profiles and durability of response 1.

Practical Implementation

1. Start PEG 17 g daily with adequate hydration
2. Titrate dose based on symptom response over 1-2 weeks
3. If inadequate response, add or switch to bisacodyl 5 mg daily for short-term use
4. If refractory, consider prescription secretagogues (lubiprostone, linaclotide, plecanatide, or prucalopride)
5. Throughout treatment, ensure adequate hydration and monitor for signs of dehydration or acute kidney injury

The stepwise approach prioritizes cost-effectiveness, safety, and evidence-based efficacy while accounting for the specific GI risks associated with Mounjaro therapy 1, 2.